Tissue Regenix Group looking to expand sales beyond the US
March 27, 2023 at 03:05 am
Share
(via NewsDirect)
Tissue Regenix Group PLC (AIM:TRX, OTC:TSSNF) chief executive Danny Lee and chief financial officer David Cocke visit Proactive's London studio to speak with Thomas Warner after releasing final results for 2022.
They explain why they believe 2022 was a "transformational" year for the Group, before looking ahead to what investors can expect next.
Lee says that Tissue Regenix is "in the process of getting the regulatory approvals" to enable it to sell its products in markets beyond the US.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
uk@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source Press Releases
Tissue Regenix Group plc is a medical device company in regenerative medicine. The principal activity of the Company is the exploitation of platform technologies in the field of bone graft substitutes and soft tissue. It is focused on the development of regenerative products utilizing its two platform technologies, dCELL, addressing soft tissue needs, and BioRinse, providing sterile bone allografts. Its divisions include dCELL, BioRinse and GBM-V. The Company's patented decellularization technology (dCELL) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Its proprietary BioRinse technology platform is primarily utilized to provide sterile tissue prepared in a manner to minimize the negative effects of processing. GBM-V produces tissue preparations for ophthalmology, primarily cornea, using conventional, classical methods.